Avid Bioservices, Inc.

    Avid Bioservices, Inc.

    NNASDAQ:CDMO
    12.49
    USD
    0.00
    (0.00%)
    2012 Y
    2013 Y
    2014 Y
    2015 Y
    2016 Y
    2017 Y
    2018 Y
    2019 Y
    2020 Y
    2021 Y
    2022 Y
    2023 Y
    2024 Y
    TTM
    Revenue per Share
    1.28
    1.26
    0.97
    1.03
    1.44
    1.55
    1.14
    0.96
    1.06
    1.65
    1.95
    2.4
    2.21
    2.37
    Basic EPS, GAAP
    -3.53
    -1.73
    -1.55
    -2.07
    -1.95
    -0.88
    -0.56
    -0.16
    -0.27
    0.12
    2.08
    - -
    -2.23
    -2.39
    Free Cash Flow per Basic Share
    -3.14
    -1.27
    -1.26
    -1.73
    -1.57
    -1.15
    -0.63
    -0.23
    0.04
    0.37
    -0.76
    -1.45
    -0.33
    -0.15
    Dividend per Share
    - -
    - -
    0.01
    0.13
    0.13
    0.12
    0.09
    0.08
    0.08
    0.08
    - -
    - -
    - -
    - -
    Book Value per Share
    -28.31
    -21.39
    -17.46
    -17.39
    -16.48
    -14.48
    -11.88
    -10.01
    -10.14
    -9.61
    -7.02
    -6.92
    -9.05
    -9.35
    Tangible Book Value per Share
    0.79
    1.38
    2.93
    2.26
    1.62
    1.44
    1.18
    0.95
    0.74
    1.34
    2.84
    3.04
    0.96
    0.7
    Basic Weighted Avg Shares
    12
    17
    23
    26
    31
    37
    47
    56
    56
    58
    61
    62
    63
    64
    Sales/Revenue/Turnover
    15
    22
    22
    27
    44
    58
    54
    54
    60
    96
    120
    149
    140
    150
    Operating Margin (%)
    -276.18
    -130.76
    -159.39
    -188.56
    7.86
    2.24
    -36.14
    -10.49
    -17.73
    12.77
    12.89
    2.41
    -13.35
    -13.55
    Depreciation Expense
    1
    1
    1
    1
    2
    2
    3
    3
    3
    3
    4
    7
    11
    12
    Net Income, GAAP
    -42
    -30
    -35
    -50
    -56
    -28
    -22
    -4
    -10
    11
    128
    - -
    -141
    -152
    Effective Tax Rate (%)
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    83.71
    - -
    - -
    Profit Margin (%)
    -276.5
    -137.34
    -157.86
    -188.04
    -125.46
    -48.86
    -40.68
    -7.86
    -17.53
    11.7
    106.75
    0.17
    -100.6
    -101.07
    Working Capital
    7
    21
    64
    43
    24
    27
    30
    28
    15
    137
    104
    -103
    33
    22
    LT Debt
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    21
    117
    180
    47
    205
    204
    Total Equity
    9
    24
    68
    59
    50
    54
    56
    53
    42
    78
    175
    189
    61
    45
    Return on Invested Capital (%)
    - -
    - -
    - -
    - -
    6.39
    2.49
    - -
    - -
    - -
    9.25
    - -
    0.16
    - -
    - -
    Return on Capital (%)
    - -
    - -
    - -
    - -
    11.56
    5.38
    - -
    - -
    - -
    -2.51
    - -
    -0.31
    - -
    - -
    Return on Common Equity (%)
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -

    Capital Structure

    USD

    •

    in mil. unless spec.
    Apr'24
    Jul'25
    Oct'25
    ST Debt
    1
    1
    1
    LT Borrowings
    154
    154
    154
    LT Finance Leases
    51
    51
    50
    Preferred Equity and Hybrid Capital
    - -
    - -
    - -
    Shares Outstanding
    64
    64
    64
    Market Capitalization
    481
    662
    633

    Working Capital

    USD

    •

    in mil. unless spec.
    Apr'24
    Jul'25
    Oct'25
    Total Current Assets
    104
    104
    97
    Cash, Cash Equivalents & STI
    38
    33
    33
    Accounts Receivable, Net
    17
    21
    18
    Inventories
    30
    29
    28
    Total Current Liabilities
    71
    71
    74
    Payables & Accruals
    21
    20
    9
    ST Debt
    1
    1
    1
    Deferred Revenue
    40
    38
    52

    Growth Rates

    USD

    •

    in mil. unless spec.

    (avg. rate of change)

    10 years
    5 years
    1 year
    Total Equity
    10.79%
    25.92%
    -67.81%
    Free Cash Flow
    50.3%
    107.65%
    -76.96%
    Net Income, GAAP
    -5,366.44%
    -10,712.94%
    -54,444.79%
    Sales/Revenue/Turnover
    22.34%
    23.05%
    -6.27%
    Total Cash Common Dividend
    - -
    - -
    - -

    Quarterly Revenue

    USD

    •

    in mil. unless spec.

    Year

    Q1
    Q2
    Q3
    Q4
    FY
    2023
    37
    35
    38
    40
    149
    2024
    38
    25
    34
    43
    140
    2025
    40
    33
    - -
    - -
    - -

    Quarterly Earnings Per Share

    USD

    •

    in mil. unless spec.

    Year

    Q1
    Q2
    Q3
    Q4
    FY
    2023
    0.02
    -0.01
    - -
    - -
    - -
    2024
    -0.03
    -0.15
    -0.09
    - -
    -2.23
    2025
    -0.09
    -0.27
    - -
    - -
    - -

    Quarterly Dividends Per Share

    USD

    •

    in mil. unless spec.

    Year

    Q1
    Q2
    Q3
    Q4
    FY
    2023
    - -
    - -
    - -
    - -
    - -
    2024
    - -
    - -
    - -
    - -
    - -
    2025
    - -
    - -
    - -
    - -
    - -

    Company Description

    Company Profile APIChatGPT
    Address
    Similar Companies
    Business

    Company News

    Company News APIChatGPT

    • prnewswire.com

      Scinai Reports Significant Revenue Growth in First Nine Months of 2026 as CDMO Business Expands

    • gurufocus.com

      Kimball Electronics, Inc. Announces Date For Reporting First Quarter Fiscal Year 2027 Financial Results

    • gurufocus.com

      Samsung Biologics Reports Third Quarter 2026 Financial Results

    • prnewswire.com

      Scinai CEO Updates Shareholders on CDMO Growth and Extended Runway Following Completed Financing

    • accessnewswire.com

      With Section 232 Tariffs Reshaping Biotech, Valion Bio's Velocity Bioworks Capitalizes on Domestic CDMO Surge

    • newsfilecorp.com

      BioHarvest Advances Proprietary Olive Cell Asset to Commercial Readiness, Opening New CDMO Licensing Opportunity

    • prnewswire.com

      Scinai Expands CDMO Business with $5.1 Million Development and Clinical Manufacturing Agreement

    • globenewswire.com

      Marker Therapeutics Highlights Expanded Manufacturing Support of CDMO Partner Following Formation of Kincellis Advanced Therapies

    • gurufocus.com

      Piramal Pharma Solutions Advances Sustainability Efforts with Solar Power Plant Addition at Morpeth, UK Site

    • prnewswire.com

      Scinai Concludes PC111 Arrangements and Refocuses Capital on NanoAb Platform and Growing CDMO Business

    • gurufocus.com

      Samsung Biologics publishes prospectus for PolyPeptide public tender offer

    • gurufocus.com

      4basebio and Genezen Enter into Strategic Collaboration to Advance Synthetic, Cell-Free DNA Platforms for Next-Generation Viral Vector Manufacturing

    • prnewswire.com

      Scinai Reports First Half 2026 Corporate Highlights and Results with Spotlight on Growing CDMO Momentum

    • prnewswire.com

      Scinai Strengthens CDMO Leadership with Appointment of Eran Kuratz as Head of Supply Chain and Business Process Administration

    • gurufocus.com

      Samsung Biologics announces all-cash offer to acquire PolyPeptide, accelerating multi-modality strategy and expanding global network across U.S., Europe, and India

    • businesswire.com

      Kimball Electronics Acquires European-Based Medical CDMO, Helvoet Polymer Technologies B.V.

    • gurufocus.com

      Piramal Pharma Solutions Highlights Strong Performance Across More Than 200 Customer Audits

    • globenewswire.com

      Resilience Announces Relocation of West Coast Headquarters to Ohio and Expansion of Sterile Manufacturing Capabilities

    • globenewswire.com

      Propanc Biopharma's CEO Tours European CDMO & Plans for GMP Production of PRP for Phase 1b, FIH Study

    • gurufocus.com

      Valion Bio (NASDAQ: VBIO) Confirms U.S. House Armed Services Committee Initiative to Address Urgent Need for Radiation /Nuclear Countermeasures